Gemtuzumab ozogamicin (GO) as monotherapy and in combination with hypomethylation agents in the treatment of acute myeloid leukemia: a systematic meta-analysis
Objectives To explore whether the addition of HMA to GO could bring additional clinical benefits to AML patients.Background Several studies have shown the HMA plus GO combination showed exciting results. However, the comparison of the clinical efficacy and safety profile of this combination with GO...
Enregistré dans:
| Auteurs principaux: | , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Taylor & Francis Group
2022-12-01
|
| Collection: | Hematology |
| Sujets: | |
| Accès en ligne: | https://www.tandfonline.com/doi/10.1080/16078454.2022.2042964 |
| Tags: |
Pas de tags, Soyez le premier à ajouter un tag!
|